United States · Remote solely · $60k–$73k/yr
EvenUp Law
Backed byBessemer Venture PartnersAbout EvenUp Law
EvenUp Law is the leading proactive AI platform for personal injury law firms. It delivers intelligent automations that streamline routine workflows and client communication. By handling administrative tasks, EvenUp empowers legal teams to concentrate on strategy and client relationships. This approach increases efficiency and responsiveness for personal injury practices.
Open positions · 19
San Francisco · Hybrid · $178k–$209k/yr
San Francisco · Hybrid · $178k–$260k/yr
San Francisco · Hybrid · $202k–$238k/yr
Toronto · Hybrid · $150k–$245k/yr
Toronto · Hybrid · $131k–$170k/yr
Atlanta · Hybrid · $250k/yr
San Francisco · Hybrid · $128k–$270k/yr
San Francisco · Hybrid · $178k–$268k/yr
Toronto · Hybrid · $176k–$250k/yr
Toronto · Hybrid · $120k–$215k/yr
San Francisco · Remote ok · $144k–$195k/yr
San Francisco · Remote ok · $187k–$253k/yr
Toronto · Hybrid · $160k–$215k/yr
Toronto · Hybrid · $160k–$215k/yr
United States · Remote ok · $212k–$301k/yr
San Francisco · Hybrid · $196k–$265k/yr
United States · Remote ok · $60k–$75k/yr
San Francisco · Remote ok · $190k–$249k/yr
Company at a glance
Investors
- SignalFireSeries E

- Lightspeed Venture PartnersSeries E

- B Capital GroupSeries E

- Bessemer Venture PartnersSeries E

- Bain Capital VenturesSeries D

- Premji InvestSeries D

- Reed Elsevier VenturesSeries E

- Bain CapitalSeries E

- HarbourVest PartnersSeries E

- Adams Street PartnersSeries E

- BroadLight CapitalSeries E

- Clio VenturesSeries B

Location
Funding History
Life at EvenUp Law
Frequently asked questions
Companies similar to EvenUp Law
Arceus is building the legal infrastructure layer for modern companies by combining experienced attorneys with intelligent technology to deliver high-quality legal services at the speed growing businesses demand. The company addresses a critical gap between legal teams' need to move faster across commercial, product, privacy, procurement, and operational work and the outdated tools and delivery models currently available. By transforming legal judgment and playbooks into scalable, innovative products, Arceus aims to reinvent how companies receive legal support. Operating in a trillion-dollar market with significant demand for its solutions, the company is positioned to fundamentally change the way modern businesses access and manage legal expertise.
9 Mothers Defense develops fast and cost-effective counter-small UAS (C-sUAS). The company uses AI for detection, tracking and defensive systems to protect against aerial threats, building AI-powered machines designed to intercept and neutralize Group 1/sUAS threats in real time. Operating in the defense industry with a focus on immediate threat countermeasures, it pursues mission-critical work countering immediate real-world aerial threats. Meaningful early equity for foundational owners and direct roadmap influence give employees a seat at the table shaping product and technology trajectory from day one, with zero red tape allowing them to make technical decisions autonomously. An on-site team in Austin, Texas builds robots, sensors and models to control them from scratch, using Python and Rust on embedded hardware, and their work spans vision, acoustics, radar and control systems across hardware and software.
Aira is an AI platform designed for procedural specialties that serves as the payer intelligence layer for medical device companies and surgical practices. The company automates critical back-office workflows while handling the full payer compliance lifecycle, including benefits verification, medical necessity determinations, prior authorization, and appeals management. By functioning as the intelligence layer powering market access teams, Aira helps healthcare providers and device manufacturers navigate the complexity of reimbursement processes to increase patient access to needed procedures. The platform addresses a key pain point in healthcare operations by streamlining the administrative burden that often delays care and complicates market entry for medical innovations.



